Gene silencing of TGF-β1 enhances antitumor immunity induced with a dendritic cell vaccine by reducing tumor-associated regulatory T cells (Q39423559)

11 September 2017

Gene silencing of TGF-β1 enhances antitumor immunity induced with a dendritic cell vaccine by reducing tumor-associated regulatory T cells (English)

1 reference

11 September 2017

0 references

1 reference

Helen Conroy

1

0 references

author name string

Karen C Galvin

series ordinal

2

1 reference

PubMed ID

22193988

11 September 2017

Sarah C Higgins

series ordinal

3

1 reference

PubMed ID

22193988

11 September 2017

Kingston H G Mills

series ordinal

4

1 reference

11 September 2017

23 December 2011

1 reference

Cancer Immunology, Immunotherapy

11 September 2017

1 reference

11 September 2017

61

1 reference

11 September 2017

3

1 reference

11 September 2017

425-431

1 reference

https://scigraph.springernature.com/pub.10.1007/s00262-011-1188-y

11 September 2017

0 references

cites work

Combinatorial treatments including vaccines, chemotherapy and monoclonal antibodies for cancer therapy

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1188-Y

Dendritic cells as therapeutic vaccines against cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1188-Y

Regulatory T cells: friend or foe in immunity to infection?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1188-Y

Regulatory T cells, tumour immunity and immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1188-Y

Mechanisms of suppression by suppressor T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1188-Y

Immunosuppressive networks in the tumour environment and their therapeutic relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1188-Y

Tumor evasion of the immune system by converting CD4+CD25- T cells into CD4+CD25+ T regulatory cells: role of tumor-derived TGF-beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1188-Y

Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1188-Y

Cutting edge: TGF-beta induces a regulatory phenotype in CD4+CD25- T cells through Foxp3 induction and down-regulation of Smad7

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1188-Y

Suppression of antitumor immunity by IL-10 and TGF-beta-producing T cells infiltrating the growing tumor: influence of tumor environment on the induction of CD4+ and CD8+ regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1188-Y

Extended dose ipilimumab with a peptide vaccine: immune correlates associated with clinical benefit in patients with resected high-risk stage IIIc/IV melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1188-Y

Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1188-Y

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1188-Y

Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1188-Y

RNAi and small interfering RNAs in human disease therapeutic applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1188-Y

Toll-like receptor 4-mediated innate IL-10 activates antigen-specific regulatory T cells and confers resistance to Bordetella pertussis by inhibiting inflammatory pathology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1188-Y

Attenuating regulatory T cell induction by TLR agonists through inhibition of p38 MAPK signaling in dendritic cells enhances their efficacy as vaccine adjuvants and cancer immunotherapeutics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1188-Y

Cancer immunotherapy: moving beyond current vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1188-Y

Mechanism of TGF-beta signaling to growth arrest, apoptosis, and epithelial-mesenchymal transition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1188-Y

Transforming growth factor-beta and the immune response: implications for anticancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1188-Y

FOXO3 programs tumor-associated DCs to become tolerogenic in human and murine prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1188-Y

Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1188-Y

10.1007/S00262-011-1188-Y

21 January 2018

Identifiers

DOI

1 reference

11 September 2017

1 reference

PubMed ID

22193988